Kardiologie up2date 2010; 6(4): 283-287
DOI: 10.1055/s-0030-1255990
Hotline – Koronare Herzerkrankung und Atherosklerose

© Georg Thieme Verlag KG Stuttgart · New York

Statine in der Primärprävention der koronaren Herzkrankheit

Mahir  Karakas, Wolfgang  Koenig
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
13. Januar 2011 (online)

Abstract

Besides its potent LDL-cholesterol lowering effect, statins have proven to be beneficial in secondary prevention of myocardial infarction, reduce stroke, and also total mortality. Although the evidence of a beneficial role in secondary prevention is unequivocal, their role in primary prevention is still discussed controversially.

Literatur

  • 1 Libby P, Crea F. Clinical Implications of inflammation for cardiovascular primary prevention.  Eur Heart J. 2010;  31 777-783
  • 2 The Emerging Risk Factors Collaboration . C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis.  Lancet. 2010;  375 132-140
  • 3 Davignon J. Beneficial cardiovascular pleiotropic effects of statins.  Circulation. 2004;  109 39-43
  • 4 Shepherd J, Cobbe S M, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia.  N Engl J Med. 1995;  333 1301-1307
  • 5 Downs J R, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.  JAMA. 1998;  279 1615-1622
  • 6 Nakamura H, Arakawa K, Itakura H et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial.  Lancet. 2006;  368 1155-1163
  • 7 Ridker P M, Danielson E, Fonseca F A et al. Rosuvastatin to prevent events in men and women with elevated C-reactive protein.  N Engl J Med. 2008;  359 2195-2207
  • 8 Koenig W, Ridker P M. Rosuvastatin for primary prevention in patients with European systematic coronary risk evaluation risk ≥ 5 % or Framingham risk > 20 %: post hoc analyses of the JUPITER trial requested by European health authorities.  Eur Heart J. 2010;  [Epub ahead of print]
  • 9 Genest J, McPherson R, Frohlich J et al. 2009 Canadian cardiovascular society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendation.  Can J Cardiol. 2009;  25 567-579
  • 10 Brugts J J, Yetgin T, Hoeks S E et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomized controlled trials.  BMJ. 2009;  338 b2376

Prof. Dr. Wolfgang Koenig

Universitätsklinikum Ulm
Zentrum für Innere Medizin
Klinik für Innere Medizin II

Albert-Einstein-Allee 23
89081 Ulm

eMail: wolfgang.koenig@uniklinik-ulm.de

    >